These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16871480)

  • 41. Neurobehavioral Sequelae of Psychostimulant Abuse.
    Djamshidian A
    Int Rev Neurobiol; 2015; 120():161-77. PubMed ID: 26070757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Being partial to psychostimulant addiction therapy.
    Pulvirenti L; Koob GF
    Trends Pharmacol Sci; 2002 Apr; 23(4):151-3. PubMed ID: 11931978
    [No Abstract]   [Full Text] [Related]  

  • 43. How fast and how often: The pharmacokinetics of drug use are decisive in addiction.
    Allain F; Minogianis EA; Roberts DC; Samaha AN
    Neurosci Biobehav Rev; 2015 Sep; 56():166-79. PubMed ID: 26116543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical studies on comorbidity between depression and psychostimulant addiction.
    Filip M; Frankowska M; Jastrzębska J; Wydra K; Przegaliński E
    Pharmacol Rep; 2013; 65(6):1529-34. PubMed ID: 24553001
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accumulation of 4-hydroxyamphetamine by rat striatal homogenates.
    Cho AK; Schaffer JC; Fischer JF
    Biochem Pharmacol; 1975 Aug; 24(16):1540-2. PubMed ID: 1191311
    [No Abstract]   [Full Text] [Related]  

  • 46. Addiction to cocaine and amphetamine.
    Hyman SE
    Neuron; 1996 May; 16(5):901-4. PubMed ID: 8630246
    [No Abstract]   [Full Text] [Related]  

  • 47. Metabolism and ecology of purine alkaloids.
    Anaya AL; Cruz-Ortega R; Waller GR
    Front Biosci; 2006 Sep; 11():2354-70. PubMed ID: 16720319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addiction theory matters-Why there is no dependence on caffeine or antidepressant medication.
    Heinz A; Daedelow LS; Wackerhagen C; Di Chiara G
    Addict Biol; 2020 Mar; 25(2):e12735. PubMed ID: 30896084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine receptor hetero-oligomerization: a hypothesis for behavioral sensitization to psychostimulants.
    Tsai SJ; Hong CJ
    Med Hypotheses; 2003 Jul; 61(1):18-20. PubMed ID: 12781635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.
    Lee TH; Szabo ST; Fowler JC; Mannelli P; Mangum OB; Beyer WF; Patkar A; Wetsel WC
    Drug Alcohol Depend; 2012 Jul; 124(1-2):11-8. PubMed ID: 22356892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneous dopamine signals support distinct features of motivated actions: implications for learning and addiction.
    Saddoris MP; Siletti KA; Stansfield KJ; Bercum MF
    Learn Mem; 2018 Sep; 25(9):416-424. PubMed ID: 30115763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Forebrain dopaminergic-cholinergic interactions, attentional effort, psychostimulant addiction and schizophrenia.
    Sarter M; Bruno JP; Parikh V; Martinez V; Kozak R; Richards JB
    EXS; 2006; 98():65-86. PubMed ID: 17019883
    [No Abstract]   [Full Text] [Related]  

  • 53. Drug dependence and addiction, III: Expectation and brain function in drug abuse.
    Volkow N
    Am J Psychiatry; 2004 Apr; 161(4):621. PubMed ID: 15056504
    [No Abstract]   [Full Text] [Related]  

  • 54. Dopamine Circuit Mechanisms of Addiction-Like Behaviors.
    Poisson CL; Engel L; Saunders BT
    Front Neural Circuits; 2021; 15():752420. PubMed ID: 34858143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addiction: failure of control over maladaptive incentive habits.
    Belin D; Belin-Rauscent A; Murray JE; Everitt BJ
    Curr Opin Neurobiol; 2013 Aug; 23(4):564-72. PubMed ID: 23452942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cognitive neuroenhancement: false assumptions in the ethical debate.
    Heinz A; Kipke R; Heimann H; Wiesing U
    J Med Ethics; 2012 Jun; 38(6):372-5. PubMed ID: 22228818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychostimulant use disorder and the heart.
    Duflou J
    Addiction; 2020 Jan; 115(1):175-183. PubMed ID: 31321853
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction.
    Olière S; Joliette-Riopel A; Potvin S; Jutras-Aswad D
    Front Psychiatry; 2013 Sep; 4():109. PubMed ID: 24069004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of the effects of repeated administration of selected phenylethylamines.
    Woolverton WL
    Drug Alcohol Depend; 1986 Jun; 17(2-3):143-50. PubMed ID: 3017670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines. Proceedings of a conference. Niigata City, Japan, June 29-30, 1995.
    Ann N Y Acad Sci; 1996 Oct; 801():1-452. PubMed ID: 9729221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.